Unknown

Dataset Information

Profile of efraloctocog alfa and its potential in the treatment of hemophilia A.


ABSTRACT: Hemophilia care has improved dramatically over the past 50 years, evolving from plasma concentrates, to purified plasma proteins, to recombinant clotting factors. These collective developments allowed for home delivery of on-demand and prophylactic treatment, resulting in the reduction of hemophilia morbidity and mortality and improved quality of life. Although efficacious in treating bleeding, conventional factor products' half-lives require frequent venipuncture, which remains a significant burden to patients. Despite the remarkable advances in hemophilia care, no improvements have, until now, been made to the pharmacokinetic properties of factor products. Multiple strategies have more recently been employed to generate novel bioengineered products that, with great hope, represent the ne

SUBMITTER: George LA 

PROVIDER: S-EPMC4418388 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature